@article{476ec666063c48beab95ded876c5d8de,
title = "Interleukin-33 Induces the Enzyme Tryptophan Hydroxylase 1 to Promote Inflammatory Group 2 Innate Lymphoid Cell-Mediated Immunity",
abstract = "IL-33 is a potent activator of type 2 immune responses via the stimulation of ILC2s, but the downstream pathways triggered in these cells are poorly defined. Flamar and colleagues show that IL-33 controls tryptophan hydroxylase 1 expression in ILC2s, which is required for type 2 immunity against worm infections.",
keywords = "IL-33, ILC2s, Tph1, group 2 innate lymphoid cells, helminth infection, inflammatory ILC2s, tryptophan hydroxylase 1, type 2 immunity",
author = "Flamar, {Anne Laure} and Klose, {Christoph S.N.} and Moeller, {Jesper B.} and Tanel Mahlak{\~o}iv and Bessman, {Nicholas J.} and Wen Zhang and Saya Moriyama and Vladislava Stokic-Trtica and Rankin, {Lucille C.} and Putzel, {Gregory Garb{\`e}s} and Rodewald, {Hans Reimer} and Zhengxiang He and Lili Chen and Lira, {Sergio A.} and Gerard Karsenty and David Artis",
note = "Funding Information: We thank the members of the Artis lab for critically reading the manuscript and the epigenomics core at Weill Cornell Medicine for carrying out the RNA sequencing. The work was supported by grants from the German Research Foundation (DFG; KL 2963/1-1 and KL 2963/2-1 to C.S.N.K. and SFB 873-B11 to H.-R.R.), the European Research Council (Starting Grant 803087 to C.S.N.K. and Advanced Grant 742883 to H.-R.R.), the Novo Nordic Foundation (14052 to J.B.M.), a National Institutes of Health (NIH) fellowship (F32AI124517 to N.J.B), JSPS Overseas Research Fellowships (to S.M.), the NIH (AI074878, AI095466, AI095608, and AI102942 to D.A. and 2P01AG032959-09 to G.K.), the Burroughs Wellcome Fund (to D.A.), the Crohn's and Colitis Foundation of America (to T.M. and D.A.), Cure for IBD (to D.A.), and the Rosanne H. Silberman Foundation (to D.A.). A.-L.F. and C.S.N.K. carried out most experiments and analyzed the data with the help of J.B.M. T.M, N.J.B. W.Z. V.S.-T. L.C.R. and S.M. G.G.P. performed RNA-seq analysis. H.-R.R. L.C. Z.H. S.A.L. and G.K. provided crucial mice for the study. A.-L.F. C.S.N.K. and D.A conceived the project and wrote the manuscript with input from all co-authors. D.A. directed and financed the research. Although not related to this study, in the last 12 months D.A. has contributed to scientific advisory boards at Genentech, Pfizer, Takeda, FARE, and the KRF. All other authors declare no competing interests. Funding Information: We thank the members of the Artis lab for critically reading the manuscript and the epigenomics core at Weill Cornell Medicine for carrying out the RNA sequencing. The work was supported by grants from the German Research Foundation ( DFG ; KL 2963/1-1 and KL 2963/2-1 to C.S.N.K. and SFB 873-B11 to H.-R.R.), the European Research Council (Starting Grant 803087 to C.S.N.K. and Advanced Grant 742883 to H.-R.R.), the Novo Nordic Foundation ( 14052 to J.B.M.), a National Institutes of Health ( NIH ) fellowship ( F32AI124517 to N.J.B), JSPS Overseas Research Fellowships (to S.M.), the NIH ( AI074878 , AI095466 , AI095608 , and AI102942 to D.A. and 2P01AG032959-09 to G.K.), the Burroughs Wellcome Fund (to D.A.), the Crohn's and Colitis Foundation of America (to T.M. and D.A.), Cure for IBD (to D.A.), and the Rosanne H. Silberman Foundation (to D.A.). Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = apr,
day = "14",
doi = "10.1016/j.immuni.2020.02.009",
language = "English",
volume = "52",
pages = "606--619.e6",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "4",
}